Who
Terry Kohler
CFO and Treasurer
Company insider
Files Form 4 as: CFO and Treasurer, ADMA Biologics; Chief Financial Officer, OptiNose; Chief Financial Officer, Verrica Pharmaceuticals.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $160K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 16 Jul 2021
- Last trade
- 16 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jul 2026filed 17 Jul 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —85,130 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,363 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —136,363 at $0.00 | filing |
| 16 Jul 2026filed 17 Jul 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —85,130 at $0.00 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —6,950 | filing |
| 21 May 2025filed 21 May 2025 | OptiNose | SEC FORM 4 Code D | —30,541 | filing |
| 21 Feb 2025filed 26 Feb 2025 | OptiNoseoption or derivative | SEC FORM 4 Code A | —6,950 at $0.00 | filing |
| 21 Feb 2025filed 26 Feb 2025 | OptiNose | SEC FORM 4 Code A | —13,875 at $0.00 | filing |
| 7 Oct 2024filed 7 Oct 2024 | OptiNoseoption or derivative | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 7 Oct 2024filed 7 Oct 2024 | OptiNose | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 27 Aug 2024filed 28 Aug 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K7,899 at $2.46 | filing |
| 26 Aug 2024filed 28 Aug 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $58K21,820 at $2.66 | filing |
| 15 Mar 2024filed 19 Mar 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 15 Mar 2024filed 19 Mar 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Nov 2023filed 16 Nov 2023 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $29K9,632 at $2.97 | filing |
| 14 Nov 2023filed 16 Nov 2023 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $54K18,452 at $2.93 | filing |
| 24 Aug 2023filed 6 Feb 2025 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 24 Aug 2023filed 28 Aug 2023 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.